Fluvoxamine Beats Placebo in Long COVID Fatigue Trial

It's March 30, I'm Cory with the story.

This is Canada News Today, driven by AI.

A new study shows a cheap antidepressant called fluvoxamine can cut down fatigue from

long COVID.

Researchers from McMaster University in Canada let a trial with 399 adults and the drug

beat out a placebo big time.

It's one of the first meds proven to tackle this tough symptom.

Long COVID hits about 65 million people worldwide, leaving them wiped out for months after

their infection.

Think ongoing tiredness, shortness of breath, aches and sleep issues that mess with daily

life like work or hanging out, or hanging out.

The team also tested midformin, a diabetes drug, but it didn't help fatigue once symptoms

set in.

Doctors and patients have been waiting for real options and this feels like a breakthrough.

The lead researcher called it a key move forward since the drugs are already out there, safe

and super affordable.

Narik's run less than $1 A.

Tablet.

Fluvoxamine had a 99% chance of working better than nothing, plus it boosted quality of

life scores.

The trial ran 60 days in Brazil with help from U.S. and Canadian spots by the University

of British Columbia.

Heads up, the full results dropped March 31 in a top medical journal so keep an eye

out.

Could mean real relief rolling out soon for folks.

Still battling this.